PE20230386A1 - Analogos del nucleosido biciclico y monociclico para el tratamiento de la hepatitis e - Google Patents

Analogos del nucleosido biciclico y monociclico para el tratamiento de la hepatitis e

Info

Publication number
PE20230386A1
PE20230386A1 PE2022002242A PE2022002242A PE20230386A1 PE 20230386 A1 PE20230386 A1 PE 20230386A1 PE 2022002242 A PE2022002242 A PE 2022002242A PE 2022002242 A PE2022002242 A PE 2022002242A PE 20230386 A1 PE20230386 A1 PE 20230386A1
Authority
PE
Peru
Prior art keywords
hepatitis
treatment
bicyclic
nucleoside analogs
monocyclic nucleoside
Prior art date
Application number
PE2022002242A
Other languages
English (en)
Inventor
Tim Hugo Maria Jonckers
Frederik Pauwels
Yannick Debing
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of PE20230386A1 publication Critical patent/PE20230386A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un compuesto para usar en el tratamiento de una infeccion por hepatitis E en un sujeto que lo necesita, caracterizado porque el compuesto se selecciona del grupo que consiste segun la figura, entre otros.
PE2022002242A 2020-04-14 2021-04-13 Analogos del nucleosido biciclico y monociclico para el tratamiento de la hepatitis e PE20230386A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20169480 2020-04-14
PCT/EP2021/059504 WO2021209419A1 (en) 2020-04-14 2021-04-13 Bi- and monocyclic nucleoside analogs for treatment of hepatitis e

Publications (1)

Publication Number Publication Date
PE20230386A1 true PE20230386A1 (es) 2023-03-06

Family

ID=70289599

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002242A PE20230386A1 (es) 2020-04-14 2021-04-13 Analogos del nucleosido biciclico y monociclico para el tratamiento de la hepatitis e

Country Status (15)

Country Link
US (1) US20230310481A1 (es)
EP (1) EP4135715B1 (es)
JP (1) JP2023522615A (es)
KR (1) KR20230002592A (es)
CN (1) CN115515603A (es)
AR (1) AR121836A1 (es)
AU (1) AU2021255809A1 (es)
BR (1) BR112022020825A2 (es)
CA (1) CA3174790A1 (es)
CL (1) CL2022002804A1 (es)
ES (1) ES2982564T3 (es)
MX (1) MX2022012904A (es)
PE (1) PE20230386A1 (es)
UY (1) UY39172A (es)
WO (1) WO2021209419A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952966A1 (en) * 2014-06-24 2015-12-30 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
JP2023522615A (ja) 2023-05-31
ES2982564T3 (es) 2024-10-16
AR121836A1 (es) 2022-07-13
CA3174790A1 (en) 2021-10-21
MX2022012904A (es) 2023-01-24
WO2021209419A1 (en) 2021-10-21
CL2022002804A1 (es) 2023-03-31
EP4135715C0 (en) 2024-05-08
BR112022020825A2 (pt) 2022-11-29
KR20230002592A (ko) 2023-01-05
UY39172A (es) 2021-10-29
EP4135715A1 (en) 2023-02-22
EP4135715B1 (en) 2024-05-08
US20230310481A1 (en) 2023-10-05
AU2021255809A1 (en) 2022-12-15
CN115515603A (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
ECSP19011209A (es) Compuestos terapéuticos
UY37997A (es) Agentes antivirales contra la hepatitis b
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
ECSP22061711A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CO2021008055A2 (es) Heterociclos funcionalizados como agentes antivirales
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
ECSP20029558A (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb)
ES2980497T3 (es) Tratamiento de la hidradenitis supurativa mediante inhibidores de JAK
DOP2018000183A (es) Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos
PE20230386A1 (es) Analogos del nucleosido biciclico y monociclico para el tratamiento de la hepatitis e
CR20110184A (es) Inhibidores de la integrasa del vih
CO2024006742A2 (es) Compuestos terapéuticos para la infección por el virus del vih
AR104173A1 (es) Variantes de protoxina ii y métodos de uso
ECSP21031085A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
CO2024001102A2 (es) Compuestos de pirazolopiridinona
CR20220553A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
CR20170466A (es) Material de implante compuesto
AR128711A1 (es) Métodos para tratar carcinoma microcítico de pulmón
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
PE20230559A1 (es) Medicamentos antivirales para el tratamiento y prevencion de la infeccion por vih
CO2024007160A2 (es) Agentes contra el paludismo